Eric K. Rowinsky
Microbiology
Biogen
Austria
Biography
ric K. Rowinsky, M.D., has served on our Board of Directors since 2010. Dr. Rowinsky is a member of our Compensation and Management Development Committee, Corporate Governance Committee and Science and Technology Committee. Dr. Rowinsky has served as President of RGenix, Inc., a privately-held life sciences company, since November 2015 and as its Executive Chairman since December 2015. From January 2012 to November 2015, Dr. Rowinsky was the Head of Research and Development and Chief Medical Officer of Stemline Therapeutics, Inc., a biotechnology company focusing on the discovery and development of therapeutics targeting cancer stem cells. Dr. Rowinsky is also an adjunct professor of medicine at New York University and has been an independent consultant since January 2010. Prior to that, he was the Chief Medical Officer of Primrose Therapeutics, Inc., a start-up biotechnology company focusing on the development of therapeutics for polycystic kidney disease, from August 2010 until its acquisition in September 2011.
Research Interest
Microbiology